The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What do the preliminary results of the MANIFEST trial say about CPI-0610 in treating MF?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Alessandro Vannucchi, University of Florence, IT, about what preliminary results of the MANIFEST trial say about CPI-0610 in treating myelofibrosis?

Vannucchi discusses results from the MANIFEST trial evaluating a BET inhibitor CPI-0610, as a monotherapy or in combination with ruxolitinib, in patients that are transfusion-dependent or independent.


Share: